The Department of Justice has concluded a yearlong probe finding that UCLA’s David Geffen School of Medicine used race as a deciding factor in admissions, and the fallout raises tough questions about fairness, federal funding, and the mission of training capable doctors. This piece walks through the DOJ’s findings, the school’s response, and the broader stakes for medical training and constitutional principles. I lay out what was found, what officials said, and why accountability matters for taxpayers and patients alike.
The DOJ’s Civil Rights Division says it uncovered evidence showing intentional racial selection in UCLA’s medical school admissions. Investigators concluded leaders at the David Geffen School of Medicine “intentionally selected applicants based on their race,” a charge that hits at the core of merit-based selection. For many conservatives this is not just a legal matter, it’s a moral one: public institutions should reward achievement, not satisfy demographic targets.
The report also calls out a particular justification the school used, labeling it “dubious.” The DOJ cited UCLA’s “dubious contention that patients receive the best care when treated by a doctor of the same race, rather than by the most qualified.” That line exposes the tension between well-meaning diversity efforts and the practical need to prioritize competence in medicine.
Investigators reported a measurable pattern: Black and Hispanic applicants admitted, on average, had lower academic qualifications than admitted white and Asian applicants. That contrast matters in a field where competence directly affects patient outcomes. Republicans argue that when admissions favor race over academic performance, public trust and public safety suffer.
The department emphasized the legal stakes because medical schools get substantial federal support. The DOJ’s finding is that the school’s practices violated civil rights laws by intentionally discriminating on the basis of race, and federal funding raises the government’s responsibility to enforce the law. For people who pay taxes and expect fair treatment from public institutions, this kind of finding cannot be shrugged off.
Assistant Attorney General Harmeet Dhillon of the DOJ’s Civil Rights Division put the criticism plainly: “UCLA’s admissions process has been focused on racial demographics at the expense of merit and excellence — allowing racial politics to distract the school from the vital work of training great doctors,” Assistant Attorney General Harmeet Dhillon of the DOJ’s Civil Rights Division stated. “Racism in admissions is both illegal and anti-American, and this Department will not allow it to continue.” Those words frame the DOJ’s position as not merely procedural but constitutional.
First Assistant United States Attorney Bill Essayli did not soften the language. He said, “Federal law and the Supreme Court precedent are clear: Race discrimination has no place in our nation’s institutions of higher learning.” “The pattern of illegal and odious conduct by UCLA’s medical school is abhorrent to our Constitution and our nation’s founding principles,” Essayli added. Those statements signal that the DOJ sees this as a precedent-setting enforcement action.
UCLA’s medical school pushed back, emphasizing its review process and commitment to opportunity. A spokesperson said the admissions process is “based on merit” and “grounded in a rigorous, comprehensive review of each applicant.” The statement continued, “We are confident in our practices and our mission to maintain access to a high-quality education to all qualified students,” the spokesperson told the Times. “We are carefully reviewing the Department of Justice’s report. The David Geffen School of Medicine is committed to providing equal opportunity to all applicants and fully complying with federal and state laws.” Those reassurances will be scrutinized against the DOJ’s evidence.
The dispute is now part legal, part political. Republicans will push for concrete remedies and oversight given the federal role in funding higher education, while defenders of campus diversity programs will argue about nuance and purpose. But when admissions choices affect both taxpayer dollars and patient care, the conversation becomes less theoretical and more urgent.
What comes next is likely to involve enforcement steps and closer scrutiny of admissions policies across taxpayer-funded institutions. If the DOJ’s findings stand, adjustments to how schools balance race, qualification, and federal compliance are likely unavoidable. For those who want qualification to matter first, this report is a call to action—and a reminder that public institutions must answer to the rule of law, not to political optics.
